Chief Executive Officer
(she/her/hers)
Amélie McFadyen is one of the driving forces behind HPV Global Action. With a Masters in Sexology- Research and Intervention from Université du Québec à Montréal and a wealth of professional experience spanning from executive directorship to lecturing, Amélie is at the forefront of HPV education and advocacy.
In her role as Chief Executive Officer of HPV Global Action, Amélie spearheads innovative programs, collaborates with international organizations, and facilitates access to free and equitable HPV vaccination and cervical screening programs for all, worldwide. Her leadership extends beyond organizational management; she provides expert guidance on sexual and reproductive health matters, leveraging her background in research and community engagement to drive meaningful change.
Amélie’s contributions have been recognized through various awards and honors, underscoring her dedication to improving public health outcomes. From adapting sexual health programs for diverse communities to collaborating with international organizations, her work embodies a commitment to innovation and inclusivity in the pursuit of global sexual and reproductive health equity.
With a focus on evidence-based interventions and collaborative partnerships, Amélie McFadyen continues to be a driving force in the fight against HPV-related and other gynecological cancers.
Publications
COVID-19 Won’t Be the Last (Or Worst) Pandemic: It’s Time to Build Resilience Into Our Cervical Cancer Elimination Goals
Marc Steben, MD; Teresa Norris; Zeev Rosberger, PhD
Design of the HPV-automated visual evaluation (PAVE) study: Validating a novel cervical screening strategy
Silvia de Sanjosé,1,2 Rebecca B Perkins,3 Nicole Campos,4 Federica Inturrisi,1 Didem Egemen,1 Brian Befano,5,6 Ana Cecilia Rodriguez,1 Jose Jerónimo,1 Li C Cheung,1 Kanan Desai,1 Paul Han,7 Akiva P Novetsky,8 Abigail Ukwuani,1 Jenna Marcus,9 Syed Rakin Ahmed,10,11,12,13 Nicolas Wentzensen,1 Jayashree Kalpathy-Cramer,10,14 and Mark Schiffman1, On behalf of the PAVE Study Group
What can NGOs do in communicating HPV prevention
Amelie Mc Fadyen, MA; Teresa Norris, MA; Thérèse Lethu, PhD; Jennifer Smith, PhD, MPH
Canada’s Role in Accelerating Global Elimination of Cervical Cancer
Marc Steben, MD; George Wurtak, MED; Silvia de Sanjosé, MD; Marina Salvadori, MD; Francois Coutlée, MD; Alberto Severini, MD; Salah Mahmud, MD; Eduardo Franco, DrPH; Ann N. Burchell, PhD; Hélène M. Gagné, MD; James Bentley, MB ChB; Laurie Elit, MD; Magali Lecavalier-Barsoum, MD; Deborah Dudgeon, MD; Nitika Pant Pai, MD; Angela Karellis, MSc; Catherine Popadiuk, MD; Laurie W. Smith, RN(C); Teresa Norris; Amelie McFadyen, MA; Jennifer Blake, MD; Roger Simard, B. Pharm
Joanne Otis; Amélie McFadyen; Thomas Haig; Martin Blais; Joseph Cox; Bluma Brenner; Robert Rousseau; Gilbert Émond; Michel Roger; Mark Wainberg; The Spot Study Group
A mixed two-dose vaccination schedule: Not enough evidence to support a policy change in Quebec
Zeev Rosberger; Marc Steben; Teresa Norris; Amelie McFadyen; Gilla K. Shapiro